NasdaqGS:INCYBiotechs
What Incyte (INCY)'s Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders
In mid-June 2026, Mirum Pharmaceuticals and Incyte reported pivotal PROGRESS Phase 2 data and an FDA Priority Review for zilurgisertib in ultra-rare fibrodysplasia ossificans progressiva, alongside positive INCA033989 Phase 1 results in myeloproliferative neoplasms and Phase 3 frontMIND data showing improved progression-free survival for tafasitamab plus lenalidomide and R-CHOP in high-risk DLBCL and HGBL.
Taken together, these updates highlight Incyte’s expanding presence in targeted...